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Homologous recombination (gene targeting) has many desirable
features for gene therapy, because it can precisely correct mutant
genes and restore their normal expression, and random nonho-
mologous integration of DNA is infrequent in cells in which
homologous recombination has occurred. There are, however, no
reports of attempts to use homologous recombination to correct
mutant genes in normal hematopoietic stem cells (HSCs), which are
prime cells for therapy of a variety of hematological and other
conditions, presumably because of their low abundance and un-
certainty that homologous recombination can occur at a usable
frequency in these cells. The experiments reported here encourage
optimism in this respect by demonstrating targeted correction of a
defective hypoxanthine phosphoribosyltransferase gene in hema-
topoietic progenitor cells that can form colonies in methylcellulose
culture. These clonogenic cells are in the same lineage as HSCs but
are more abundant and more mature and so less pluripotent.
Corrected colonies were identified by their survival in selective
medium after electroporation of correcting DNA into unfraction-
ated mouse bone marrow cells and were confirmed by reverse
transcription–PCR and sequencing. The observed frequency (4.4 6
3.3 3 1025 per treated clonogenic cell) is the same as in embryonic
stem cells (2.3 6 0.4 3 1025) with the same DNA and mutation.
These data suggest that gene targeting to correct mutant genes
eventually will prove feasible in HSCs capable of long-term bone
marrow reconstitution.
The ideal form of gene therapy would correct a mutant genedirectly without causing changes elsewhere in the genome
(1). Many of the problems associated with gene therapy would
thereby be greatly reduced or eliminated, including lack of
adequate expression, extinction of expression, and the mutagen-
esis associated with integrating the correcting sequences into
random sites in the genome. Homologous recombination has the
necessary prerequisites for use in this context, because it is
capable of precisely correcting mutant genes (2), and random
nonhomologous integration of targeting DNA into the genome
is infrequent in cells in which homologous recombination has
occurred (3). However, we find no reported attempts of using
homologous recombination to correct mutant genes in normal
hematopoietic stem cells (HSCs; ref. 4), which are prime cells for
therapy of a variety of hematological and other conditions (5).
The likely reasons appear to be the low abundance of these cells
combined with uncertainty that homologous recombination can
occur in them at a usable frequency. The experiments we report
here were designed to test the possibility of using homologous
recombination to correct a mutant gene in hematopoietic pro-
genitor cells that can form colonies in tissue culture. These
colony-forming cells (CFCs) are in the same lineage as HSCs but
are more abundant and more mature, and therefore less pluri-
potent. We demonstrate that the hypoxanthine phosphoribosyl-
transferase (HPRT) gene, which is mutated in humans with
Lesch-Nyhan disease (6, 7), can be corrected by homologous
recombination in CFCs at frequencies equivalent to those seen
in embryonic stem (ES) cells, encouraging optimism that ho-
mologous recombination to correct mutant genes in pluripotent
stem cells capable of long-term hematopoietic repopulation
eventually will prove feasible.
Materials and Methods
Hprt2 Bone Marrow (BM) Cells and ES Cells. Hprt2 BM cells were
isolated from C57BLy6J-Hprtb-m3 mice descended from
E14TG2a ES cells (8) and were obtained from The Jackson
Laboratory. ES cells (HM-1), isolated from mice derived from
E14TG2a ES cells, were from David W. Melton (University of
Edinburgh, Edinburgh, U.K.; ref. 9).
Reconstruction Experiments. Assays were in 24-well plates with
mixtures of Hprt1 cellsyHprt2 cells: 5 3 104y5 3 105; 5 3
103y5 3 105; and 5 3 103y5 3 106, and in 35-mm dishes when the
mixtures were 5 3 103y5 3 107 and 5 3 102y5 3 107. The mixtures
were plated in standard methylcellulose medium (MethoCult GF
M3434; StemCell Technologies, Vancouver) containing the fol-
lowing recombinant cytokines: mouse stem cell factor (50 ng/
ml)ymouse IL-3 (10 ng/ml)yhuman IL-6 (10 ng/ml)yhuman
erythropoietin (3 units/ml)ybovine pancreatic insulin (10 mg/
ml). Selection was with HAT (120 mM hypoxanthine/0.4 mM
aminopterin/20 mM thymidine). Colonies were counted under
dark-field illumination at day 14.
Electroporation. Electroporations were performed with a cuvette
having a gap size of 4 mm and an area of 160 mm2 (BTX, San
Diego) with a 1-s pulse from a 250 mF capacitator charged to 300
V. BM and ES cells were suspended at a density of 0.3–1.5 3 108
cells/ml in conventional ES-cell medium (10, 11), containing
DMEM with 15% heat-inactivated FBS and 10 mM 2-mercap-
toethanol. Linearized correcting DNA was 1.6–5 nM. After
electroporation at room temperature, the cell suspensions were
held at room temperature for 5–10 min before plating.
Correcting DNA Plasmid. The MP8neo plasmid used for preparing
correcting DNA has a copy of the pMC1neo gene (not used in these
experiments) between the 59 homologous region and the promoter
region of the MP8 plasmid described (ref. 3; Fig. 1C). The MP8neo
plasmid DNA was linearized with BamHI before use.
Selection of HAT-Resistant Colonies. BM cells were flushed from
the femur and tibia by using DMEM with 10% heat-inactivated
FBS and made into a single-cell suspension by repeated passage
through an 18-gauge needle; 5–10 3 107 BM cells from individ-
ual male mice were electroporated in 0.5–0.8 ml of medium and
plated in 35-mm dishes (1 ml per dish) after mixing with 10 ml
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of methylcellulose culture medium (MethoCult GF M3434;
StemCell Technologies). Cell numbers did not exceed 1 3
107/ml. One milliliter of twice final concentration HAT (23 5
240 mM hypoxanthine/0.8 mM aminopterin/40 mM thymidine)
was added along the wall to each dish of cells 2 days after
electroporation. These conditions support the growth of HAT-
resistant clonogenic progenitor cells. The input numbers of
CFCs were determined by culturing 5 3 104 BM cells in 1 ml of
the same methylcellulose medium without HAT. Colonies were
counted under dark-field illumination at day 14. The procedure
used for gene targeting in ES cells was essentially as described
(10) except that HAT selection was imposed 2 days after
electroporation.
Reverse Transcription–PCR (RT-PCR) Analyses and Sequencing of Tran-
scripts. HAT-resistant colonies were picked under a dissecting
microscope and washed with 200 ml of cold PBS. Preparation of
RNA and cDNA synthesis using an oligo(dT) primer were with
a Cells-to-cDNA kit supplied by Ambion (Austin, TX). PCR
conditions were: 94°C for 2 min, then 35 cycles of 94°C for 30 s,
58°C for 1 min, and 72°C for 1 min. The primers were 59-
TCCTCCTCCTGAGCAGTCAG-39 (for human exon 1), and
59-ATCTCCACCAATAACTTTTATGTCCC-39 (for mouse
exon 4). The expected PCR product was 402 bp. The quality of
the tested RNA was confirmed by PCR with primers specific for
the murine glyceraldehyde-3-phosphate dehydrogenase gene,
59-GTTCCAGTATGACTCCACTCACG-39 and 59-AGATC-
CACGACGGACACATTG-39, which gives a 597-bp fragment.
PCR products were electrophoresed in 2% agarose gel and
stained with ethidium bromide. The 402-bp PCR product was
isolated and purified by QIAquick (Qiagen, Chatsworth, CA)
and sequenced by using an automatic DNA sequencer (Applied
Biosystems).
Results
To establish conditions able to detect homologous recombina-
tion events in a clonogenic assay, we first carried out recon-
struction experiments with mixtures of wild-type and mutant BM
cells. BM cells were prepared from male mice having a partial
deletion of the X-linked Hprt gene; these Hprt2 cells are killed
by HAT-containing medium. We also prepared BM cells from
wild-type mice having a functional Hprt gene; these Hprt1 cells
survive in HAT-containing medium. Mixtures were made with
decreasing numbers of wild-type Hprt1 BM cells added to an
excess of Hprt2 BM cells in ratios ranging from 1/10 to 1/100,000,
thereby simulating the correction of the Hprt2 BM cells at
frequencies ranging from 1021 to 1025. The mixtures were plated
in a standard methylcellulose medium for murine clonogenic
hematopoietic progenitor cells, but in the presence of HAT. The
numbers of colonies, and so of CFCs, counted at day 14, were
normalized to a constant number of treated cells, and plotted
against the input ratio of Hprt1 to Hprt2 cells (Fig. 1 A). The
data show that the progressively decreasing numbers of Hprt1
average numbers and their standard deviations. (B) Strategy to detect gene
targeting in hematopoietic CFCs. BM cells are prepared from an Hprt-deficient
male mouse, electroporated in the presence of correcting DNA, and plated in
methylcellulose medium. Two days later, HAT-selection medium is added (see
Materials and Methods). (C) Gene targeting at the Hprt locus. The structures
of the mutant Hprt locus in C57BL/6J-Hprtb-m3 mice (Top line), correcting DNA
(Middle line), and corrected targeted locus (Bottom line) are shown. The
correcting DNA is 12 kb in length and includes two 3-kb regions of homology
with the target gene. Black boxes represent exons; heavy horizontal lines
represent mouse sequences; open boxes and lines indicate that in the correct-
ing DNA the HPRT promoter (P) and its first exon are derived from the human
HPRT gene. Neo indicates a neomycin-resistance gene (not used in these
experiments). The dashed light line indicates plasmid sequences. The paren-
theses show a 55-kb deletion in the mutant gene.
Fig. 1. Reconstruction experiment and strategy for gene targeting in BM
cells. (A) Reconstruction experiment. Mixtures were made with decreasing
numbers of wild-type Hprt1 BM cells added to an excess of mutant Hprt2 BM
cells in ratios ranging from 1/10 to 1/100,000 to simulate the correction of the
mutant Hprt2 cells at frequencies ranging from 1021 to 1025. Colonies were
counted at day 14 in a HAT-containing methylcellulose medium (see Materials
and Methods), and the number of CFCs (CFCs per 5 3 107 BM cells) was plotted
against the ratio of Hprt1 to Hprt2 cells. The center and error bars indicate
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(HAT-resistant) colonies are readily detected in the presence of
an increasingly vast excess of Hprt2 BM (HAT-sensitive) cells.
No signs of deviation from linearity were observed even when
the proportion of Hprt1 colonies was only 1 in 100,000. The
presence of a large number of dying cells (HAT kills dividing
Hprt2 cells in about 3 days) reduces the sizes of the individual
colonies, but the linearity of the plot in Fig. 1 A shows that this
does not affect the colony count.
Our procedure for assaying homologous recombination in
hematopoietic colony-forming progenitors is illustrated in Fig. 1
B and C. BM cells are isolated from descendants of mice
originally generated by Hooper et al. (8) from an ES cell that is
Hprt2 as a consequence of a spontaneous 55-kb deletion (12)
that includes the promoter and exons 1 and 2 of the Hprt gene.
The correcting DNA, which has '6 kb of its sequence homol-
ogous to the target locus, supplies the missing promoter and
exons after homologous recombination (Fig. 1C). We introduce
correcting DNA into the Hprt2 BM cells by electroporation, the
treated cells are plated in methylcellulose, an equal volume of 23
HAT medium is added after 2 days, and the number of HAT-
resistant (Hprt1) colonies are counted 12 days later. Because the
mutation in the Hprt2 BM cells is a deletion, which never reverts
to Hprt1 spontaneously, no background of false-positive HAT-
resistant cells occurs. The colony assay consequently counts the
number of CFCs that have been corrected by homologous
recombination. Dividing this number by the total number of
CFCs in the BM sample at the time of electroporation gives the
frequency of gene correction.
Six experiments were carried out, each with between 7 and
12 3 107 unfractionated BM cells from a single adult male Hprt2
mouse. The total number of nucleated Hprt2 cells treated (cell
no.) and the number of CFCs in this total (input CFC) are
presented in Table 1. In the first two experiments, the input
numbers of CFCs were calculated on the assumption that 1025
BM cells contain 200 CFCs, a figure derived from the data in Fig.
1A, which were obtained with BM cells from mice of a similar
age. In the remaining four experiments, the input numbers of
CFCs were directly assayed by counting colonies formed in the
absence of HAT selection and without electroporation. The
frequency of gene correction ranged from 1.2 to 9.2 per 105 input
CFCs, with a mean and standard deviation of 4.4 6 3.3 3 1025.
This frequency is a conservative estimate, because no corrections
were made for cells killed by the electroporation. One experi-
ment failed to yield any HAT-resistant colonies, but this result
is not unexpected statistically because the input number of CFCs
in this BM sample was low (0.3 3 105).
The HAT-resistant colonies derived from Hprt2 BM cells
after gene correction were indistinguishable in gross appearance
from the colonies derived from wild-type BM cells cultured in
the presence of a comparable excess (.1003) of Hprt2 BM cells
(Fig. 2A Left). The types of cell present in the wild-type and
corrected colonies, as judged from cytospin preparations (Fig.
2A Right), were likewise indistinguishable. Typically both in-
cluded granulocytes and macrophages, indicating that they were
derived from hematopoietic progenitors capable of yielding
more than one type of fully differentiated cell.
To check whether the HAT-resistant colonies obtained in
these experiments were truly the result of correction of their
mutant Hprt genes by homologous recombination in the pre-
dicted manner, we devised a RT-PCR assay that amplifies a
recombinant RNA fragment that is present only in cells in which
the mutation has been corrected in the predicted manner. The
assay uses one primer that hybridizes to sequences in exon 1 of
the human HPRT gene, which is present in the correcting DNA
but not in the mouse BM cells. The other primer hybridizes to
exon 4 of the mouse Hprt gene, which is present in the target
mouse BM cells but not in the correcting DNA. Thus, specific
PCR amplification can occur only when a human/mouse chi-
meric mRNA is synthesized after the juxtaposition of human
exon 1 and mouse exon 4 as a result of homologous recombi-
nation at the Hprt genomic locus. The size of the PCR product
should be 402 bp. The ethidium bromide-stained gel illustrated
in Fig. 2B shows that the recombinant RNA fragment is present
in HAT-resistant colonies resulting from correction of the Hprt2
mutation, as judged by the predicted 402-bp PCR product, but
is absent in noncorrected Hprt2 cells. The recombinant RNA is
also absent in normal Hprt1 control cells that synthesize Hprt
mRNA having only mouse sequences (data not shown). Confir-
mation of the RT-PCR result was obtained by sequencing the
chimeric 402-bp PCR product by using a primer corresponding
to mouse exon 4 (Fig. 2C). The nucleotide sequence of exon 1
of the PCR product was human (the relevant positions are
underlined); the nucleotide sequence of its exon 2 was mouse.
ES cells generally are recognized as efficient in homologous
recombination. To serve as a comparative standard for the
frequency of recombination in the BM CFCs, we therefore
assayed the frequency of gene correction in HM-1 ES cells (9),
which carry the same mutation as the Hprt2 donor mice. The
bottom three lines of Table 1 list the correction frequencies in
HM-1 cells by using the same correcting DNA as in the BM
experiments but with electroporation conditions optimized for
ES cells. The average frequency of gene correction was 2.3 6
0.4 3 1025, which is not significantly different from that ob-
served in the BM CFCs, 4.4 6 3.3 3 1025. We conclude that
clonogenic hematopoietic progenitor cells are capable of medi-
ating homologous recombination at a frequency comparable to
that seen in ES cells.
Discussion
This demonstration of gene correction by homologous recom-
bination in hematopoietic progenitor cells opens the way to
correcting cells of this category with a view to gene therapy that
provides short-term hematopoietic support (13). It also should
encourage investigators to approach the task of achieving tar-
geted gene correction in the more primitive HSCs that are
capable of populating BM long term. We recognize that our
currently demonstrated frequency of gene correction in hema-
topoietic CFCs is low. We also recognize that, although the exact
numbers are debatable, HSCs represent a smaller fraction of BM
cells than do the CFCs that we have corrected (which occur at
a frequency of approximately two per 103 nucleated BM cells).
Assays for HSCs are based on their capacity to provide long-term













BM (Hprtb-m3) 7.3 1.5* 9 6.0
BM (Hprtb-m3) 12 2.4* 10 4.2
BM (Hprtb-m3) 8.5 0.3† 0 NA
BM (Hprtb-m3) 12 4.8† 8 1.7
BM (Hprtb-m3) 10 2.5† 3 1.2
BM (Hprtb-m3) 10 1.2† 11 9.2
4.4 6 3.3‡
ES (HM-1) 2.0 NA 420 2.1
ES (HM-1) 1.5 NA 300 2.0
ES (HM-1) 2.0 NA 564 2.8
2.3 6 0.4‡
CFC, colony-forming cells; HATr, HAT resistant; and NA, not applicable.
*Assuming 200 CFCy105 BM cells, as calculated from the data in Fig. 1A.
†Number determined directly by a clonogenic assay without HAT selection.
‡Means 6 standard deviation.
















Fig. 2. Analyses of HATr colonies. (A) Typical HATr colonies (Left, dark field) and their component cells (Right, Wright–Giemsa-stained cytospin) from (Upper)
wild-type BM cells mixed with Hprt2 BM cells and (Lower) corrected Hprt2 BM cells. M, macrophage; and G, granulocyte. (B) RT-PCR analyses to detect corrected
Hprt transcripts. The diagram shows the corrected Hprt gene and the recombinant mRNA structure. The open box is human exon 1; the black boxes are mouse
exons 2–9. The PCR analyses to test for gene targeting use a human-specific primer (h) from the first exon and a mouse primer (m) from the fourth exon. The
photograph shows gel electrophoresis of the PCR products obtained when individual HATr colonies were analyzed by RT-PCR by using these primers. The 402-bp
fragment was obtained with the HATr colonies (1, 2, and 3), which contain chimeric human-mouse transcripts from the corrected Hprt gene, but was not obtained
with noncorrected (NC) cells. The same samples were tested with glyceraldehyde-3-phosphate dehydrogenase (GAPDH) primers which amplify a 597-bp
fragment. (C) Nucleotide sequence of RT-PCR product from a HATr colony. The printed nucleotide sequences are from human HPRT cDNA (Top line), mouse cDNA
(Middle line), and the 402-bp PCR product sequenced with a primer corresponding to mouse exon 4 (Bottom line). The gel scan from the automatic DNA sequencer
is shown. The first exon of the PCR product is identical to the human HPRT sequence, and the second exon is identical to the mouse Hprt sequence. Capital letters
highlight the first exon of human and second exon of the mouse. Underlining shows the differences between human and mouse.
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hematopoietic repopulation in recipient animals, and estimates
of their numbers depend on the assay system used. Assays in
which marrow cells are transplanted into lethally irradiated
recipients (14) suggest a frequency of approximately one HSC
per 105 nucleated BM cells, whereas those using lethally irradi-
ated wild-type recipients also receiving short-term populating
cells (15) or sublethally irradiated (16) and nonirradiated recip-
ients (17) whose endogenous HSCs are genetically handicapped
suggest a higher frequency (approximately one per 104 nucleated
BM cells). These differences probably reflect the effects of
radiation damage to the BM microenvironment (18), so that the
higher estimate (one HSC per 104 marrow cells) is more appli-
cable to the present discussion. In this case, if HSCs are corrected
at the same frequency as CFCs (approximately one event per 2 3
104 cells), an average of 2 3 108 cells would be required for a
single HSC correction event to be detected, which is approxi-
mately the number of marrow cells obtainable from four mice.
This number of cells could not be injected into a single recipient
mouse, and so some form of enrichment for stem cells would be
desirable, such as the use of commercially available antibody-
coated magnetic beads to discard the majority of unwanted cells
but retain a subfraction that includes HSCs.
Our optimism with regard to the feasibility of gene correction
in HSCs is supported by the fact that electroporation is versatile
and applicable to a wide variety of cell types (19). Moreover, the
overall effectiveness of gene correction in HSCs is open to
substantial improvements by modifying various parts of our
experimental procedure. First, by doubling the length of the
homologous sequences in the input DNA, the targeting fre-
quency can be increased more than 10-fold (20). Second, the
proportion of repopulating HSCs in the BM can be increased at
least 10-fold by pretreatment with suitable cytokines (21). Third,
additional genetic material can be introduced into the target
locus at the time the HSCs are corrected to provide them with
an advantage in engraftment and/or enhance their proliferation
in vivo. For example, a transgene encoding a truncated eryth-
ropoietin receptor sensitive to exogenously administered eryth-
ropoietin is a demonstrated example of such a benign advantage
sequence (22). A transgene encoding a chimeric protein that
dimerizes and induces cell growth when exposed to a chemical
inducer of dimerization is another example (23). Predicting the
overall improvement in the effectiveness of HSC gene correction
achievable by these strategies alone or in combination is difficult,
but an improvement of more than 2 orders of magnitude is
conceivable. Finally, it appears reasonable to expect that the
long-sought goal of expanding HSCs ex vivo (24) eventually will
be reached.
Whereas our optimism of achieving gene correction in HSCs
at a usable frequency may be justified, there are still serious
obstacles to consider. For example, therapeutic gene targeting in
human subjects presents problems of genetic heterogeneity that
are not observed in isogeneic experimental mice. Additionally,
targeting at the Hprt locus occurs at a relatively high frequency
and automatically provides a selectable marker for targeted cells;
the frequency of targeting at therapeutically more important loci
is likely to be less, and direct selection of corrected cells will not
usually be possible. Our experiments are nonetheless encourag-
ing because they clearly demonstrate that gene correction by
homologous recombination can be achieved in clonogenic pro-
genitor cells, which are in the same lineage as HSCs capable of
long-term BM engraftment.
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